Dr. Martens (LON:DOCS) Insider Ije Nwokori Acquires 197 Shares

Dr. Martens plc (LON:DOCS) insider Ije Nwokori bought 197 shares of Dr. Martens stock in a transaction that occurred on Thursday, December 11th. The stock was purchased at an average cost of GBX 76 per share, for a total transaction of £149.72.

Ije Nwokori also recently made the following trade(s):

• On Tuesday, November 11th, Ije Nwokori purchased 176 shares of Dr. Martens stock. The shares were purchased at an average cost of GBX 85 per share, with a total value of £149.60.
• On Wednesday, October 15th, Ije Nwokori sold 298,675 shares of Dr. Martens stock. The stock was sold at an average price of GBX 90, for a total value of £268,807.50.
• On Monday, October 13th, Ije Nwokori acquired 167 shares of Dr. Martens stock. The shares were purchased at an average price of GBX 89 per share, for a total transaction of £148.63.
• On Wednesday, October 8th, Ije Nwokori acquired 136 shares of Dr. Martens stock. The shares were purchased at an average cost of GBX 90 per share, for a total transaction of £122.40.

Dr. Martens Price Performance

LON:DOCS traded up GBX 0.50 during mid-day trading on Friday, reaching GBX 77.45. The stock had a trading volume of 6,999,042 shares, compared to its average volume of 2,302,026. The stock has a market capitalization of £748.44 million, a P/E ratio of 45.56, a P/E/G ratio of 6.40 and a beta of 0.11. The firm has a 50 day moving average price of GBX 85.14 and a two-hundred day moving average price of GBX 82.29. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. Dr. Martens plc has a one year low of GBX 43.02 and a one year high of GBX 100.87.

Dr. Martens (LON:DOCS) last issued its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. As a group, analysts expect that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 27th. Peel Hunt reaffirmed a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of GBX 6,000.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.